{"studyId":"prad_su2c_2019","cancerTypeId":"prad","name":"Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)","description":"Whole exome sequencing of 444 castrate resistant prostate cancer tumor/normal pairs. SU2C-PCF Dream Team: Precision Therapy for Advanced Prostate Cancer.","publicStudy":true,"pmid":"31061129","citation":"Abida et al. PNAS 2019","groups":"","status":1,"importDate":"2026-01-16 18:21:41","allSampleCount":444,"sequencedSampleCount":444,"cnaSampleCount":444,"mrnaRnaSeqSampleCount":0,"mrnaRnaSeqV2SampleCount":0,"mrnaMicroarraySampleCount":0,"miRnaSampleCount":0,"methylationHm27SampleCount":0,"rppaSampleCount":0,"massSpectrometrySampleCount":0,"completeSampleCount":0,"referenceGenome":"hg19","treatmentCount":0,"structuralVariantCount":178,"cancerType":{"id":"prad","name":"Prostate Adenocarcinoma","dedicatedColor":"Cyan","shortName":"PRAD","parent":"prostate"},"readPermission":true,"resourceCounts":[]}